BioGeneration Ventures

Avidicure is a biotechnology company developing a dual agonistic, multifunctional antibody modality engineered for targeted cancer immunotherapy. Its AVC-Boosters are designed to engage immune cells with high avidity and to localize activation within tumors, enabling potent anti-tumor activity as monotherapy while reducing off-target effects. The approach aims to advance oncology therapies by combining immune engagement with tumor-specific activation to support immune responses and potentially improve safety profiles.

Rhygaze is a biotechnology company focused on developing innovative gene therapies aimed at restoring vision in individuals affected by blindness-related diseases. The company’s therapy utilizes advanced technology to deliver a light-sensor gene directly to cone cells that have lost their light sensitivity. By repairing these cells' ability to detect light, Rhygaze seeks to enable effective vision restoration for patients. Through its specialized approach, the company aims to make significant contributions to the healthcare industry and improve the quality of life for those facing vision loss.

Citryll is a private pharmaceutical company based in Oss, The Netherlands, established in 2015. The company specializes in the development of pharmaceutical drugs aimed at treating autoimmune and other human diseases. Citryll's innovative approach focuses on the formation, function, and clearance of neutrophil extracellular traps (NETs) that are associated with the protein citrullination pathway, which is catalyzed by Peptidylarginine Deiminase (PAD) enzymes. This research and development are instrumental in providing treatment options for various conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

Kivu Biosciences, based in San Francisco, is a biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for cancer treatment. The company aims to deliver superior therapeutics and rapidly advance transformative assets, operating discreetly while focusing on its innovative pipeline.

Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications.

Rhygaze is a biotechnology company focused on developing innovative gene therapies aimed at restoring vision in individuals affected by blindness-related diseases. The company’s therapy utilizes advanced technology to deliver a light-sensor gene directly to cone cells that have lost their light sensitivity. By repairing these cells' ability to detect light, Rhygaze seeks to enable effective vision restoration for patients. Through its specialized approach, the company aims to make significant contributions to the healthcare industry and improve the quality of life for those facing vision loss.

Artica Therapeutics is a biotechnology company focused on the research and development of innovative therapies aimed at treating severe autoimmune and inflammatory disorders. The company employs label-free cellular-based screening methods, which facilitate the rapid advancement of drug candidates through the development process. This approach enables healthcare professionals to more effectively address the needs of patients suffering from these complex conditions. Additionally, Artica Therapeutics is involved in the development of medical devices and pharmaceutical processes, underscoring its commitment to advancing healthcare solutions.

Tessellate BIO is a biotechnology company focused on oncology, developing precision therapies that leverage synthetic lethality to treat cancers with significant unmet medical needs. It targets tumors dependent on synthetic lethality mechanisms to create targeted treatments, supported by ongoing research and development in cancer biology and pharmaceutical processes.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

Dualyx is a biotechnology company focused on the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company specializes in the creation of immune modulators, particularly Treg-targeted therapies, which are designed to suppress undesirable autoimmune responses in patients. Through its innovative approach, Dualyx aims to provide lasting treatments that offer potential cures for those suffering from autoimmune conditions.

A preclinical-stage company developing a precision medicine diagnostic platform. This platform enables patient stratification based on complement-activation profiles, potentially serving as an efficacy biomarker in future clinical studies.

Founded in 2022, Panome Bio specializes in biomarker discovery through its metabolomics platform. It offers services including untargeted analysis and proprietary computational methods for metabolomics, lipidomics, and proteomics screening.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

FundaMental Pharma is a neuroscience company developing novel drugs targeting neurodegeneration. Its portfolio focuses on preclinical stage therapies designed to uncouple the physiological function of glutamate-gated NMDA receptors from their toxic effects, aiming to stop neurodegeneration and improve brain health.

Phosphoenix is a neurotechnology company that specializes in developing innovative solutions for vision restoration. Originating from the NESTOR program, which received support from the Netherlands Organisation for Scientific Research, the company was founded by a team of accomplished neuroscientists, electronic engineers, and entrepreneurs. Phosphoenix focuses on creating a chronically implanted wireless device that bypasses the eyes and interfaces directly with the brain. This technology is designed to restore functional vision for individuals who have lost their sight, allowing users to recognize objects, navigate independently, and improve their overall quality of life. By leveraging fundamental insights from neuroscience, Phosphoenix aims to translate these advancements into practical clinical applications.

Scenic Biotech develops genomics and immunotherapy technologies to unlock genetic suppressors as new drug targets for cancer and rare genetic diseases. The company focuses on disease suppressing genes that can counteract disease-causing mutations, enabling rapid identification and validation of novel targets for medicines. By leveraging genomics to identify modifiers that suppress or block the effects of harmful genes, Scenic Biotech aims to create disease-modifying therapies that address the genetic drivers of severe illnesses.

A preclinical-stage company developing a precision medicine diagnostic platform. This platform enables patient stratification based on complement-activation profiles, potentially serving as an efficacy biomarker in future clinical studies.

River BioMedics is a biotech company developing 3D human cardiac tissue models for preclinical drug discovery and toxicity screening. These tissues mimic the structure and function of the human heart and provide clinically relevant readouts to assess a compound's effects on cardiac performance and safety. The company uses a stem cell-based, multidisciplinary approach to generate models that support target validation and the discovery and development of novel cardiac therapies.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Dunad Therapeutics is a biopharmaceutical company focused on developing next-generation targeted protein degradation therapies. It provides a proprietary, tunable covalent chemistry platform that enables discovery and development of medicines that selectively and durably target disease drivers. The platform integrates disease biology with advanced chemistry to modulate protein stability and conformation, allowing the targeting of often undruggable proteins and enabling high-precision, durable therapeutic effects.

A preclinical-stage company developing a precision medicine diagnostic platform. This platform enables patient stratification based on complement-activation profiles, potentially serving as an efficacy biomarker in future clinical studies.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

Citryll is a private pharmaceutical company based in Oss, The Netherlands, established in 2015. The company specializes in the development of pharmaceutical drugs aimed at treating autoimmune and other human diseases. Citryll's innovative approach focuses on the formation, function, and clearance of neutrophil extracellular traps (NETs) that are associated with the protein citrullination pathway, which is catalyzed by Peptidylarginine Deiminase (PAD) enzymes. This research and development are instrumental in providing treatment options for various conditions, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis, and organ damage resulting from sepsis.

Azafaros B.V., based in Leiden, the Netherlands, specializes in the development of therapeutic agents aimed at treating rare metabolic disorders, specifically lysosomal storage disorders. The company focuses on innovative oral medications made from aza-sugar compounds, which were originally discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC, and have been exclusively licensed to Azafaros. These promising therapeutic agents are designed to address critical disease pathways by targeting the central nervous system and altering the metabolism of glycosphingolipids through a unique dual mode of action. Azafaros seeks to improve patient outcomes and enhance the quality of life for individuals affected by these severe inherited conditions.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Tiga TX develops an IgA therapeutic monoclonal antibody platform to activate neutrophils for the treatment of solid tumors.

Fibrocor Therapeutics L.P. is a biotechnology company based in Toronto, Canada, established in 2017. The company specializes in developing tissue-specific therapeutics aimed at treating the underlying causes of fibrotic diseases affecting the kidneys and other organs. Fibrocor focuses on disease-modifying therapeutics for fibrosis and has identified a lead program for which it collaborates with Evotec to develop novel molecules. Utilizing patient-derived tissue samples, Fibrocor's innovative platform uncovers critical pathways in the fibrogenic process, facilitating the identification of new disease targets and the development of a comprehensive pipeline of therapeutics.

Dualyx is a biotechnology company focused on the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company specializes in the creation of immune modulators, particularly Treg-targeted therapies, which are designed to suppress undesirable autoimmune responses in patients. Through its innovative approach, Dualyx aims to provide lasting treatments that offer potential cures for those suffering from autoimmune conditions.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.

NewAmsterdam Pharma, established in 2019 and headquartered in Naarden, the Netherlands, is a late-stage biopharmaceutical company dedicated to improving patient care in cardio-metabolic disease populations. The company's primary focus is the development of transformative therapies, with its lead product, obicetrapib, being a next-generation, oral, low-dose CETP inhibitor designed to lower LDL-C levels more effectively than current treatments, particularly for patients with statin intolerance or Arteriosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally-tolerated statin therapy.

Genase Therapeutics is the developer of therapeutic products intended to treat solid tumors. The company develops small molecule inhibitors against a metabolic target with therapeutic potential in hematologic malignancies as well as conducting research in the field of oncology, providing pharmaceuticals and healthcare professionals with biotechnological research and development work in the field of oncology.

Azafaros B.V., based in Leiden, the Netherlands, specializes in the development of therapeutic agents aimed at treating rare metabolic disorders, specifically lysosomal storage disorders. The company focuses on innovative oral medications made from aza-sugar compounds, which were originally discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC, and have been exclusively licensed to Azafaros. These promising therapeutic agents are designed to address critical disease pathways by targeting the central nervous system and altering the metabolism of glycosphingolipids through a unique dual mode of action. Azafaros seeks to improve patient outcomes and enhance the quality of life for individuals affected by these severe inherited conditions.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

Escalier Biosciences B.V. is a biopharmaceutical company based in Nijmegen, the Netherlands, specializing in the development of small molecule therapeutics aimed at treating autoimmune disorders, particularly psoriasis. Founded in 2016, the company is engaged in creating innovative drug candidates that effectively target ROR?t, a critical regulator in the inflammatory process. Escalier's lead products, which are designed for both topical and oral administration, are currently in late-stage preclinical studies. These therapeutics are formulated to enhance penetration in dermal tissues, thereby maximizing target engagement at sites of inflammation while minimizing systemic drug activity and associated side effects. In addition to its operations in the Netherlands, Escalier has an office in Encinitas, California.

Mironid Limited is a biotechnology company based in Newhouse, United Kingdom, that specializes in drug discovery and development. Founded in 2014, Mironid focuses on creating innovative drug candidate molecules that modulate key cell signaling proteins to address degenerative kidney diseases, chronic inflammatory diseases, and cancer. The company's pipeline includes unique compounds designed to treat these conditions, utilizing a Physiology Mirroring Approach that aligns drug target environments with those found in living cells. Mironid aims to identify and validate novel drug targets, particularly in areas with significant unmet medical needs, by leveraging advanced technologies to streamline and enhance the drug discovery process. Through its dedicated efforts, Mironid seeks to develop differentiated therapies that improve patient health and quality of life.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Mellon Medical B.V., established in 2013 and based in Nijmegen, the Netherlands, specializes in the development and marketing of innovative medical suturing tools designed for surgeons. The company focuses on enhancing healthcare treatment procedures by providing advanced surgical instruments that enable single-handed stitching. This unique capability allows medical specialists to perform efficient and effective suturing of tubular and layered structures, ultimately aiming to improve patient outcomes during surgical procedures. Through its commitment to innovation in surgical technology, Mellon Medical seeks to support healthcare professionals in delivering high-quality care.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

Scenic Biotech develops genomics and immunotherapy technologies to unlock genetic suppressors as new drug targets for cancer and rare genetic diseases. The company focuses on disease suppressing genes that can counteract disease-causing mutations, enabling rapid identification and validation of novel targets for medicines. By leveraging genomics to identify modifiers that suppress or block the effects of harmful genes, Scenic Biotech aims to create disease-modifying therapies that address the genetic drivers of severe illnesses.

Cristal Therapeutics BV, established in 2011 and headquartered in Maastricht, the Netherlands, operates as a clinical-stage pharmaceutical company specializing in nanomedicine development. The company's core business revolves around its proprietary CriPec platform, which transforms drugs into nanoparticles for targeted delivery. Cristal Therapeutics focuses on treating diseases such as cancer by improving drug efficacy and safety profiles through this innovative technology.

Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, specializing in the development of innovative mucosal vaccines for infectious diseases. The company's lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infections. Mucosis utilizes its proprietary Mimopath technology, which allows for needle-free administration via the nose or mouth, effectively engaging the innate immune system through Toll-like receptor 2 (TLR2) to stimulate a robust adaptive immune response. This approach has shown promise in both animal and human proof-of-concept studies, demonstrating broad protection against various pathogens, including RSV, pneumococci, and influenza.

Cristal Therapeutics BV, established in 2011 and headquartered in Maastricht, the Netherlands, operates as a clinical-stage pharmaceutical company specializing in nanomedicine development. The company's core business revolves around its proprietary CriPec platform, which transforms drugs into nanoparticles for targeted delivery. Cristal Therapeutics focuses on treating diseases such as cancer by improving drug efficacy and safety profiles through this innovative technology.

Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, specializing in the development of innovative mucosal vaccines for infectious diseases. The company's lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infections. Mucosis utilizes its proprietary Mimopath technology, which allows for needle-free administration via the nose or mouth, effectively engaging the innate immune system through Toll-like receptor 2 (TLR2) to stimulate a robust adaptive immune response. This approach has shown promise in both animal and human proof-of-concept studies, demonstrating broad protection against various pathogens, including RSV, pneumococci, and influenza.

Synaffix BV is a clinical-stage biotechnology company based in Oss, the Netherlands, focused on developing advanced antibody-drug conjugate (ADC) technology platforms for oncology. Established in 2010, the company specializes in technologies that enhance the efficacy and tolerability of ADCs. Its flagship offering, GlycoConnect, utilizes enzymatic modification of naturally occurring glycan anchor points on antibodies to enable efficient, site-specific, and stable conjugation of potent anti-cancer agents. Additionally, Synaffix provides HydraSpace, a linker technology designed to improve payload solubility and reduce aggregation potential. The company's portfolio also includes a metal-free click chemistry approach applicable across pharmaceutical and academic sectors. With a strong patent portfolio, Synaffix ensures protection for its innovations through at least 2035, positioning itself as a key player in the development of proprietary ADCs from a wide range of antibodies.

Staten Biotechnology B.V. is a biotechnology company based in Nijmegen, the Netherlands, established in 2014. The company focuses on researching, developing, and producing therapeutics aimed at treating dyslipidemia, a condition characterized by abnormal lipid levels that can lead to cardiovascular disease. Staten Biotechnology specializes in the development of human monoclonal antibodies designed to neutralize apoC3, a protein that plays a crucial role in triglyceride metabolism. By targeting this protein, the company's therapeutics aim to reduce lipid accumulation in the blood and subsequently lower the risk of vascular and heart diseases.

Acerta Pharma is focused on the development of covalent binding technology solutions to create therapies for cancer. Acerta Pharma was acquired by AstraZeneca in February 2016. Acerta Pharma was founded in 2013 and is based in San Carlos, California.

Dezima Pharma B.V., founded in 2012 and located in Naarden, the Netherlands, specializes in the development of protein-based compounds aimed at treating cardiovascular diseases associated with dyslipidemia. The company focuses on creating innovative drug therapies, particularly a cholesteryl ester transfer protein inhibitor, which is designed to reduce low-density lipoprotein cholesterol levels. This pharmacological approach aims to lower the risk of cardiovascular diseases, thereby providing clinicians with effective treatment options for dyslipidemic patients.

SurgVision BV is a technology company based in 't Harde, the Netherlands, focused on developing near-infrared fluorescence molecular imaging solutions for surgical applications. Established in 2011, SurgVision specializes in high-definition fluorescence imaging platforms that enhance the ability of surgeons to differentiate between healthy and cancerous tissues during procedures. Their innovative technology employs optical imaging cameras and molecular probes, allowing for precise identification and removal of tumor tissues, particularly in breast cancer surgeries. As of October 2017, SurgVision operates as a subsidiary of Bracco Imaging S.p.A.

Lanthio Pharma B.V. is a biopharmaceutical company based in Groningen, the Netherlands, focused on the discovery and development of novel lantipeptide drugs targeting serious medical conditions such as fibrosis, stroke, heart failure, and multiple sclerosis. Founded in 2010, the company leverages its proprietary LanthioPep technology to create peptide therapeutics that exhibit enhanced resistance to degradation, high specificity for receptors, and improved intrinsic activity. Among its key products are LP2, a selective angiotensin II type 2 receptor agonist aimed at treating fibrosis; PanCyte, designed for ischemic stroke recovery and peripheral vascular disease; and a lanthi-apelin agonist targeting the APJ receptor, which plays a role in various organ systems. Lanthio Pharma is committed to advancing therapeutic options for patients suffering from these severe diseases.

Argenx is a biopharmaceutical company based in the Netherlands, dedicated to developing antibody-based therapies for rare autoimmune diseases.

Medisse is a Dutch company, founded in 2006, that develops, produces and markets resorbable soft tissue implants, based on bio-resorbable PTMC polymers. Medisse does yet not have commercial products but is working on the testing of its first product before market introduction. Medisse's first product will be an anti-adhesion barrier.

Argenx is a biopharmaceutical company based in the Netherlands, dedicated to developing antibody-based therapies for rare autoimmune diseases.

FlexGen is an innovative biotech company based in Leiden, the Netherlands. FlexGen is a spin-off from Leiden University Medical Centre (LUMC) and Dutch Space (part of EADS) and has proprietary technologies for laser based in-situ synthesis of oligonucleotides and other biomolecules. FlexGen commercializes the FlexArrayer, a bench-top instrument for custom microarray and oligopool synthesis. FlexGen works at the forefront of innovative microarray and oligopool applications.

Progentix Orthobiology is a manufacturer based in Bilthoven, Netherlands, specializing in orthopedic bone graft materials. The company focuses on developing a range of osteoinductive products designed for clinical applications in bone regenerative surgery. Progentix Orthobiology aims to enhance surgical outcomes by providing innovative solutions for spine-related procedures and minimally invasive surgeries.

Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, specializing in the development of innovative mucosal vaccines for infectious diseases. The company's lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infections. Mucosis utilizes its proprietary Mimopath technology, which allows for needle-free administration via the nose or mouth, effectively engaging the innate immune system through Toll-like receptor 2 (TLR2) to stimulate a robust adaptive immune response. This approach has shown promise in both animal and human proof-of-concept studies, demonstrating broad protection against various pathogens, including RSV, pneumococci, and influenza.

NovioGendix, established in 2008, is a Dutch molecular diagnostics company specializing in non-invasive liquid biopsy tests for prostate cancer. Based in Nijmegen, it offers services such as the PCA3 Test and PROGENSA PCA3 urine test for prostate cancer detection and management. The company also develops molecular diagnostic assays for various urologic cancers, collaborating with Radboud University Medical Center. Its shareholders include BioGeneration Ventures and Participatiemaatschappij Oost Nederland.

Azafaros B.V., based in Leiden, the Netherlands, specializes in the development of therapeutic agents aimed at treating rare metabolic disorders, specifically lysosomal storage disorders. The company focuses on innovative oral medications made from aza-sugar compounds, which were originally discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC, and have been exclusively licensed to Azafaros. These promising therapeutic agents are designed to address critical disease pathways by targeting the central nervous system and altering the metabolism of glycosphingolipids through a unique dual mode of action. Azafaros seeks to improve patient outcomes and enhance the quality of life for individuals affected by these severe inherited conditions.